JP2013545752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545752A5 JP2013545752A5 JP2013538998A JP2013538998A JP2013545752A5 JP 2013545752 A5 JP2013545752 A5 JP 2013545752A5 JP 2013538998 A JP2013538998 A JP 2013538998A JP 2013538998 A JP2013538998 A JP 2013538998A JP 2013545752 A5 JP2013545752 A5 JP 2013545752A5
- Authority
- JP
- Japan
- Prior art keywords
- genistein
- formulation
- pharmaceutical composition
- formulation according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 50
- 239000000203 mixture Substances 0.000 claims 50
- 229940045109 genistein Drugs 0.000 claims 42
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 42
- 235000006539 genistein Nutrition 0.000 claims 42
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 42
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 229920003169 water-soluble polymer Polymers 0.000 claims 13
- 239000002736 nonionic surfactant Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 238000002360 preparation method Methods 0.000 claims 6
- 230000005855 radiation Effects 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000011164 ossification Effects 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 208000001395 Acute radiation syndrome Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 229920003079 Povidone K 17 Polymers 0.000 claims 2
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 238000011161 development Methods 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 108020001823 ΔF508-CFTR Proteins 0.000 claims 2
- 206010065687 Bone loss Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000012395 formulation development Methods 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/946,711 US8900635B2 (en) | 2010-11-15 | 2010-11-15 | Nanoparticle isoflavone compositions and methods of making and using the same |
| US12/946,711 | 2010-11-15 | ||
| PCT/US2011/060829 WO2012068140A1 (en) | 2010-11-15 | 2011-11-15 | Nanoparticle isoflavone compositions & methods of making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015220365A Division JP6181733B2 (ja) | 2010-11-15 | 2015-11-10 | ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013545752A JP2013545752A (ja) | 2013-12-26 |
| JP2013545752A5 true JP2013545752A5 (OSRAM) | 2014-11-20 |
Family
ID=46047969
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538998A Pending JP2013545752A (ja) | 2010-11-15 | 2011-11-15 | ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 |
| JP2015220365A Active JP6181733B2 (ja) | 2010-11-15 | 2015-11-10 | ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 |
| JP2017140477A Pending JP2018008967A (ja) | 2010-11-15 | 2017-07-20 | ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015220365A Active JP6181733B2 (ja) | 2010-11-15 | 2015-11-10 | ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 |
| JP2017140477A Pending JP2018008967A (ja) | 2010-11-15 | 2017-07-20 | ナノ粒子イソフラボン組成物、ならびにそれを製造および使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (9) | US8900635B2 (OSRAM) |
| EP (1) | EP2640188B1 (OSRAM) |
| JP (3) | JP2013545752A (OSRAM) |
| CA (1) | CA2852410C (OSRAM) |
| IL (1) | IL226377B (OSRAM) |
| WO (1) | WO2012068140A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8900635B2 (en) | 2010-11-15 | 2014-12-02 | Humanetics Corporation | Nanoparticle isoflavone compositions and methods of making and using the same |
| US20140274966A1 (en) * | 2013-03-14 | 2014-09-18 | Hygia Pharmaceuticals, Llc | Drink Product Containing Genistein and Use Thereof |
| US9623003B1 (en) * | 2013-04-04 | 2017-04-18 | Humanetics Corporation | Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein |
| US9623004B2 (en) | 2013-08-02 | 2017-04-18 | Humanetics Corporation | Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy |
| US20150126597A1 (en) * | 2013-11-07 | 2015-05-07 | Humanetics Corporation | Genistein cancer treatment regimen maximizing cancer radiation therapy benefits |
| US9084726B2 (en) * | 2013-11-26 | 2015-07-21 | Humanetics Corporation | Suspension compositions of physiologically active phenolic compounds and methods of making and using the same |
| US20170000761A1 (en) * | 2013-11-27 | 2017-01-05 | Humanetics Corporation | Protecting tissue and mitigating injury from chemical exposure |
| TWI583404B (zh) * | 2015-07-13 | 2017-05-21 | 高雄醫學大學 | ７,３’,４’-大豆異黃酮製劑的製備方法 |
| WO2018156946A1 (en) * | 2017-02-24 | 2018-08-30 | Humanetics Corporation | Protecting tissue and mitigating injury from radiation-induced ionizing events |
| WO2018168777A1 (ja) * | 2017-03-13 | 2018-09-20 | 学校法人関西学院 | 嚢胞性線維症予防又は治療剤 |
| US11129894B2 (en) | 2017-09-29 | 2021-09-28 | - Humanetics Corporation | Sensitizing cells to proton radiation |
| JP2019099557A (ja) * | 2017-11-28 | 2019-06-24 | 日本化薬株式会社 | ベンダムスチンを含有する溶液製剤 |
| US10881634B2 (en) * | 2017-12-07 | 2021-01-05 | Hughes Biotechnology Co., Ltd | Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone |
| US20220193103A1 (en) * | 2019-04-23 | 2022-06-23 | The University Of North Carolina At Chapel Hill | Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model |
| EP4132499A4 (en) * | 2020-04-06 | 2024-05-01 | Humanetics Corporation | GENISTEIN TREATMENT OF INFLAMMATORY PULMONARY INJURY |
| EP4228600A4 (en) * | 2020-10-16 | 2024-11-06 | Humanetics Corporation | GENISTEIN SOLID DISPERSION COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME |
| EP4274552A4 (en) * | 2021-01-11 | 2025-08-06 | Humanetics Corp | GENISTEIN TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS |
| CN112843048A (zh) * | 2021-04-01 | 2021-05-28 | 郑州新泽生物科技有限公司 | 一种用于抑制雄性动物发情的液体制剂及其制备方法 |
| CN113080365B (zh) * | 2021-04-02 | 2022-12-06 | 嘉应学院 | 一种大豆素纳米粉的制备方法及其应用 |
| WO2023177676A1 (en) * | 2022-03-14 | 2023-09-21 | University Of South Florida | Genistein for asthma treatment |
| WO2023212130A1 (en) | 2022-04-28 | 2023-11-02 | GreenStone Biosciences, Inc. | Treatment of the adverse cardiovascular effects of cannabinoids |
| CN114948869A (zh) * | 2022-05-26 | 2022-08-30 | 中国药科大学 | 一种染料木素纳米混悬液的制备方法及该方法制备的染料木素纳米混悬液 |
| WO2025117337A1 (en) | 2023-11-28 | 2025-06-05 | GreenStone Biosciences, Inc. | Genistein phosphate derivatives |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390559A (en) | 1979-04-11 | 1983-06-28 | Z-L Limited Partnership | Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| JP2001309764A (ja) | 2000-05-01 | 2001-11-06 | Taiyo Kagaku Co Ltd | ポリフェノール類組成物 |
| AU2001271310B2 (en) | 2000-06-14 | 2005-10-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine Inc. | Phytoestrogenic Isoflavone Compositions, Their Preparation and Use Thereof for Protection Against and Treatment of Radiation Injury |
| US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
| JP2005531616A (ja) | 2002-06-29 | 2005-10-20 | アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | イソフラボン濃縮物およびその製造法 |
| WO2004045541A2 (en) | 2002-11-15 | 2004-06-03 | Cargill, Incorporated | Soluble isoflavone compositions |
| WO2005033279A2 (en) | 2003-09-29 | 2005-04-14 | University Of Virginia Patent Foundation | Discovery of novel soluble crystalline anesthetics |
| EP1781253A1 (en) | 2004-07-01 | 2007-05-09 | Warner-Lambert Company LLC | Preparation of pharmaceutical compositions containing nanoparticles |
| US8197851B2 (en) | 2004-09-29 | 2012-06-12 | Michael Ary Bos | Carotenoid composition and method for preparation thereof |
| UA89513C2 (uk) | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
| TWI372749B (en) | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
| AU2006309295B2 (en) | 2005-06-03 | 2012-04-26 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
| CN101212964A (zh) * | 2005-06-29 | 2008-07-02 | 帝斯曼知识产权资产管理有限公司 | 异黄酮纳米颗粒及其用途 |
| CN101212965A (zh) * | 2005-06-29 | 2008-07-02 | 帝斯曼知识产权资产管理有限公司 | 包括异黄酮纳米颗粒的局部用组合物 |
| US9743680B2 (en) | 2005-10-14 | 2017-08-29 | Wild Flavors, Inc. | Microemulsions for use in food and beverage products |
| US8353639B2 (en) * | 2005-11-18 | 2013-01-15 | Deere & Company | Turnbuckle lock |
| EP1978933A2 (en) * | 2005-12-15 | 2008-10-15 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for oral administration |
| WO2008086400A2 (en) * | 2007-01-09 | 2008-07-17 | Isp Investments Inc. | Sirtuin-activating compounds of enhanced bioavailability |
| JP2009067752A (ja) | 2007-09-14 | 2009-04-02 | Akuto Kk | 製剤の製造方法及び製剤 |
| US20110190399A1 (en) | 2008-07-31 | 2011-08-04 | Santosh Kumar Kar | Curcumin nanoparticles and methods of producing the same |
| CA2787156C (en) | 2010-01-19 | 2020-12-29 | Northwestern University | Synthetic nanostructures for delivery of oligonucleotides |
| AU2011265184B2 (en) | 2010-06-11 | 2016-08-04 | Sloan-Kettering Institute For Cancer Research | Multivalent glycopeptide constructs and uses thereof |
| US8900635B2 (en) | 2010-11-15 | 2014-12-02 | Humanetics Corporation | Nanoparticle isoflavone compositions and methods of making and using the same |
| JP5948871B2 (ja) | 2011-12-28 | 2016-07-06 | 株式会社東洋新薬 | ポリフェノール含有組成物 |
| US9084726B2 (en) | 2013-11-26 | 2015-07-21 | Humanetics Corporation | Suspension compositions of physiologically active phenolic compounds and methods of making and using the same |
-
2010
- 2010-11-15 US US12/946,711 patent/US8900635B2/en active Active
-
2011
- 2011-11-15 JP JP2013538998A patent/JP2013545752A/ja active Pending
- 2011-11-15 CA CA2852410A patent/CA2852410C/en active Active
- 2011-11-15 EP EP11840762.6A patent/EP2640188B1/en active Active
- 2011-11-15 WO PCT/US2011/060829 patent/WO2012068140A1/en not_active Ceased
-
2012
- 2012-03-02 US US13/411,405 patent/US8551530B2/en active Active
-
2013
- 2013-05-16 IL IL226377A patent/IL226377B/en active IP Right Grant
-
2014
- 2014-10-27 US US14/524,936 patent/US9308167B2/en active Active
-
2015
- 2015-11-10 JP JP2015220365A patent/JP6181733B2/ja active Active
-
2016
- 2016-03-01 US US15/057,979 patent/US9636322B2/en active Active
- 2016-09-07 US US15/258,866 patent/US9724325B2/en active Active
-
2017
- 2017-07-06 US US15/643,201 patent/US10039739B2/en active Active
- 2017-07-20 JP JP2017140477A patent/JP2018008967A/ja active Pending
-
2018
- 2018-07-03 US US16/026,546 patent/US10729674B2/en active Active
-
2020
- 2020-07-21 US US16/934,770 patent/US20210000788A1/en not_active Abandoned
-
2022
- 2022-02-10 US US17/650,594 patent/US20220370403A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545752A5 (OSRAM) | ||
| Qing et al. | Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy | |
| Liu et al. | In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin | |
| Paliwal et al. | Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: in vitro and in vivo evaluation | |
| JP2013513612A5 (OSRAM) | ||
| Li et al. | Magnetic natural lipid nanoparticles for oral treatment of colorectal cancer through potentiated antitumor immunity and microbiota metabolite regulation | |
| Xue et al. | Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma | |
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| JP2013507415A5 (OSRAM) | ||
| JP2011511072A5 (OSRAM) | ||
| NZ710383A (en) | A novel formulation of diclofenac | |
| JP2019516684A5 (OSRAM) | ||
| JP2010510241A5 (OSRAM) | ||
| BRPI0403935A (pt) | Formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
| Karanam et al. | Poly (ɛ-caprolactone) nanoparticles of carboplatin: Preparation, characterization and in vitro cytotoxicity evaluation in U-87 MG cell lines | |
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| JP2001247459A5 (OSRAM) | ||
| JP2016534142A5 (OSRAM) | ||
| JO3659B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| Zang et al. | Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer | |
| JP2013542981A5 (OSRAM) | ||
| JP2015527360A5 (OSRAM) | ||
| Peng et al. | Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy | |
| JP2012502103A5 (OSRAM) |